New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

Amber Fullmer, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Although imatinib revolutionized the management of chronic myeloid leukemia (CML), recent data indicate a transformation in the treatment approach likely in the near future. The superiority of second-generation tyrosine kinase inhibitors (TKIs) over imatinib in newly diagnosed disease has been recognized. Several investigational agents specific for those patients with the T315I mutation remain under evaluation. In Philadelphia-positive (Ph-positive) acute lymphoblastic leukemia (ALL), the addition of imatinib improved response rates. However, short remission durations with single agent therapy limit the benefit on survival. Early molecular remissions achieved with dasatinib will enable more patients to proceed to stem cell transplant (SCT), with increased likelihood of positive outcomes post-SCT.

Original languageEnglish (US)
Pages (from-to)81-91
Number of pages11
JournalLeukemia and Lymphoma
Volume52
Issue numberSUPPL. 1
DOIs
StatePublished - Feb 2011

Keywords

  • Lymphoid leukemia
  • chemotherapeutic approaches
  • myeloid leukemias and dysplasias

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this